289 related articles for article (PubMed ID: 19064754)
1. Natalizumab use in pediatric multiple sclerosis.
Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
Putzki N; Yaldizli O; Bühler R; Schwegler G; Curtius D; Tettenborn B
Eur Neurol; 2010; 63(2):101-6. PubMed ID: 20090344
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
[TBL] [Abstract][Full Text] [Related]
7. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
9. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
10. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
Berger JR
Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
Killestein J; Vennegoor A; Strijbis EM; Seewann A; van Oosten BW; Uitdehaag BM; Polman CH
Ann Neurol; 2010 Sep; 68(3):392-5. PubMed ID: 20661928
[TBL] [Abstract][Full Text] [Related]
13. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab dosage suspension: are we helping or hurting?
West TW; Cree BA
Ann Neurol; 2010 Sep; 68(3):395-9. PubMed ID: 20818793
[TBL] [Abstract][Full Text] [Related]
15. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC;
Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
[TBL] [Abstract][Full Text] [Related]
17. The role of natalizumab in the treatment of multiple sclerosis.
Coyle PK
Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
[TBL] [Abstract][Full Text] [Related]
18. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
Waubant E; Chabas D; Okuda DT; Glenn O; Mowry E; Henry RG; Strober JB; Soares B; Wintermark M; Pelletier D
Arch Neurol; 2009 Aug; 66(8):967-71. PubMed ID: 19667217
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Arnal-Garcia C; García-Montero MR; Málaga I; Millán-Pascual J; Oliva-Nacarino P; Ramió-Torrentà L; Oreja-Guevara C
Eur J Paediatr Neurol; 2013 Jan; 17(1):50-4. PubMed ID: 23021975
[TBL] [Abstract][Full Text] [Related]
20. [Natalizumab in multiple sclerosis].
Río-Izquierdo J; Montalban X
Rev Neurol; 2009 Sep 1-15; 49(5):265-9. PubMed ID: 19714558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
